A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
Feng Wang, Ming-Ming He, Jian Xiao, Yanqiao Zhang, Xianglin Yuan, Weijia Fang +24 more
Clinical Cancer Research
Abstract
High-dose vitamin C plus chemotherapy failed to show superior PFS compared with chemotherapy in patients with mCRC as first-line treatment but may be beneficial in patients with mCRC harboring RAS mutation.
Concepts
FOLFOXBevacizumabMedicineColorectal cancerOxaliplatinOncologyInternal medicineOpen label